SavedAdd your journal

Journals / Jinekoloji ve Obstetrik Derg. / 2004 / Cilt: 18 - Sayı: 3

Efficacy of oral ritodrine treatment versus no treatment following suppression of uterine contractions by intravenous ritodrine in cases of preterm labor

Erken doğum tehdidi olgularında ritodrinin sadece intravenöz verilmesi ile intravenöz tedavisinden sonra oral idame uygulamalarının karşılaştırılması

Bilgin GÜRATES
Selahattin KUMRU
Cem PARMAKSIZ
Pages
158–161
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The level of statistical significance was set at p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To compare the efficacy of oral ritodrine treatment versus no treatment following suppression of the uterine contractions by intravenous ritodrine in cases of preterm labor (PL).STUDY DESIGN: This study was undertaken in Firat University Medical School, Department of Obstetric and Gynecology between January-December 2003.
📊
Key Findings & Data:The first group (ritodrine IV, n=18) had given no treatment following suppression of uterine contractions while the second group (ritodrine IV+PO, n=20) had given oral ritodrine as the maintenance treatment.
💡
Conclusion & Impact:The level of statistical significance was set at p
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: To compare the efficacy of oral ritodrine treatment versus no treatment following suppression of the uterine contractions by intravenous ritodrine in cases of preterm labor (PL).STUDY DESIGN: This study was undertaken in Firat University Medical School, Department of Obstetric and Gynecology between January-December 2003. Thirty-eight patients hospitalized as PL and whose uterine contractions were suppressed by ritodrine, were randomly divided into two groups. The first group (ritodrine IV, n=18) had given no treatment following suppression of uterine contractions while the second group (ritodrine IV+PO, n=20) had given oral ritodrine as the maintenance treatment. All patients were given betamethasone in addition to tocolytics. Time gained from the beginning of the tocolytics to delivery, demographic characteristics of newborns, and APGAR scores were analyzed. Independent samples Student's t test and chi-square tests were used when necessary. The level of statistical significance was set at p

Özet

AMAÇ: Erken doğum tehdidi (EDT) olgularında intravenöz ritodrin ile kontraksiyonların baskılanmasından sonra oral ritodrin verilmesinin etkinliğinin, hiç tedavi verilmemesi ile karşılaştırılması.MATERYAL ve METOD: Çalışma, Ocak 2003-Aralık 2003 tarihleri arasında Fırat Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Kliniği, Obstetrik Bölümü'nde gerçekleştirildi. EDT tanısıyla yatırılarak intravenöz ritodrin ile uterus kontraksiyonları baskılanan 38 gebe, rastgele 2 gruba ayrıldı. Birinci gruba (ritodrin IV, n=18) hiçbir idame tedavisi uygulanmadı. İkinci gruba (ritodrin IV+PO, n=20) ise oral ritodrin (Prepar® tablet) (toplam 60-120 mg/gün) verildi. İlave olarak tüm hastalara tokolitik tedaviye ilave olarak betametazon verildi. Tedavinin başlangıcından doğuma kadar geçen süreler (kazanılan süreler) ile yenidoğanların demografik özellikleri ile APGAR skorları not edildi. İstatistiksel değerlendirme için gerektiğinde bağımsız örnekler t ve ki-kare testleri kullanıldı. p

🔖

Cite This Article

GÜRATES, B., KUMRU, S., PARMAKSIZ, C. (2022). Efficacy of oral ritodrine treatment versus no treatment following suppression of uterine contractions by intravenous ritodrine in cases of preterm labor. Jinekoloji ve Obstetrik Derg., Cilt: 18 - Sayı: 3, 158–161. https://ajindex.com/articles/559093

References (15)

  1. Annon Practice bulletin ACOG: Clinical manangement guidelines for obstetriciah-gynecologists number 31 assesment of risk factors for preterm birth. Obstet Gynecol 98:709-06, 2001
  2. Burke C, Morrison JJ: Perinatal factors and preterm delivery in an Irissh obstetric population. J Perinat Med 28:49-53, 2000
  3. Lumley,j: The epidemiology of preterm birth. Bailliere's Clin Obstet Gynaecol 7: 477-498, 1993
  4. Dyson DC, Danbe KH, Bamber JA, Crites YM, Field DR, Maier JA, Newman LA, Ray DA, Walton DL, Armstrong MA: Monitoring women at risk for prelerm labor. N Engl J Med 338: 54-6, 1998
  5. Koks CA, Brolmann HA, de Kleine MJ, Manger PA: A randomized comparison of nifedipine and ritodrine for suppres sion of preterm labor. Eur J Obstet Gynecol Reprod Biol 77: 171- 6,1998
  6. Cunningham FG, Gant NF, et al: Williams Obstetrics 21st edition. 689-729, 2001
  7. Garcia-Velasco JA, Gonzalez Gonzalez A: A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. Int J Gynaecol Obstet 61:239-44, 1998
  8. Holleboom CA, Merkus JM, van Elferen LW: A loading model for ritodrine administration in preterm labour. Br J Obstet Gynecol 100:1107-10, 1993
  9. Smit DA, Essed GG, de Haan J: Serum levels of ritodrine during oral maintenance therapy. Gynecol Obstet Invest 18:105- 12, 1984
  10. Van Lierde M, Desager JP, Harvengt C, Thomas K: Ritodrine serum levels: influence of dose and route of administration. Int J Clin Pharmacol Ther Toxicol 22:382-5, 1984
  11. Caritis SN, Venkataramanan R, Cotroneo M, Chiao JP: Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol 161:32-5, 1989
  12. Schiff E, Sivan E, Terry S, Dulitzky M, Friedman SA, Mashiach S, Sibai BM: Currently recommended oral regimens for ritodrine tocolysis result in extremely low plasma levels. Am J Obstet Gynecol 169:1059-64, 1993
  13. Creasy RK, Golbus MS, Laros RK Jr, Parer JT, Roberts JM: Oral ritodrine maintenance in the treatment of preterm labor. Am J Obstet Gynecol 137:212-9, 1980 14. Martin RW, Martin JN Jr, Pryor JA, Caddy DK, Wiser WL, Morrison JC: Comparison of oral ritodrine and magnesium gluconate for ambulatory tocolysis. Am J Obstet Gynecol 158:1440-5, 1988
  14. Hagay ZJ, Epstein M, Goldchmit R, Gotlib Z, Blickstein I, Zalel Y, Weissman A: A prospective randomized clinical trial comparing a new oral sustained-release ritodrine with conventional tablets. Eur J Obstet Gynecol Reprod Biol 56:83-7, 1994
  15. Witter FR, Benedetti T.I, Petty BG, Feldman AM, Trail